Cargando…

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells

SIMPLE SUMMARY: Antibody-drug conjugates (ADCs) represent an innovative class of anticancer agents specifically aimed at targeting cancer cells, reducing damage to healthy tissues but showing some weaknesses. A promising approach for the development of high-affinity tumor targeting ADCs is the use o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damiani, Isabella, Castiglioni, Silvia, Sochaj-Gregorczyk, Alicja, Bonacina, Fabrizia, Colombo, Irma, Rusconi, Valentina, Otlewski, Jacek, Corsini, Alberto, Bellosta, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389717/ https://www.ncbi.nlm.nih.gov/pubmed/34439990 http://dx.doi.org/10.3390/biology10080758

Ejemplares similares

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2017)

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1
por: Sochaj-Gregorczyk, Alicja M., et al.
Publicado: (2017)

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2018)

Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
por: Krzyscik, Mateusz A., et al.
Publicado: (2021)

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2017)

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
por: Abawi, Ariana, et al.
Publicado: (2021)

Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
por: Fu, Zhiwen, et al.
Publicado: (2023)

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
por: Świderska, Karolina Weronika, et al.
Publicado: (2018)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
por: Hingorani, Dina V., et al.
Publicado: (2022)

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
por: Cho, Hanhee, et al.
Publicado: (2022)

Cellular Effects of HER3-Specific Affibody Molecules
por: Göstring, Lovisa, et al.
Publicado: (2012)

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer
por: Cho, In Kyung, et al.
Publicado: (2022)

17AAG-induced internalisation of HER2-specific Affibody molecules
por: Göstring, Lovisa, et al.
Publicado: (2016)

Immunomodulatory activity of IR700-labelled affibody targeting HER2
por: Mączyńska, Justyna, et al.
Publicado: (2020)

The HER2-Binding Affibody Molecule (Z(HER2∶342))(2) Increases Radiosensitivity in SKBR-3 Cells
por: Ekerljung, Lina, et al.
Publicado: (2012)

Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1
por: Nawrocka, Daria, et al.
Publicado: (2023)

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload
por: Wang, Yanming, et al.
Publicado: (2017)

Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery
por: Kim, Jihoon, et al.
Publicado: (2021)

PET of HER2 Expression with a Novel (18)FAl Labeled Affibody
por: Xu, Yuping, et al.
Publicado: (2017)

Affibody-mediated PET imaging of HER3 expression in malignant tumours
por: Rosestedt, Maria, et al.
Publicado: (2015)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Min-Ho, et al.
Publicado: (2019)

Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity
por: Sokka, Iris K., et al.
Publicado: (2021)

Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer
por: Hu, Xianwen, et al.
Publicado: (2022)

Pre-Clinical Study of the [(18)F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer
por: Han, Jingya, et al.
Publicado: (2022)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo
por: Gallery, Melissa, et al.
Publicado: (2018)

Synthesis and Biological Evaluation of RGD and isoDGR–Monomethyl Auristatin Conjugates Targeting Integrin α(V)β(3)
por: Raposo Moreira Dias, André, et al.
Publicado: (2019)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death
por: Shipunova, Victoria Olegovna, et al.
Publicado: (2021)

Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging
por: Zielinski, Rafal, et al.
Publicado: (2012)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
por: Wang, Haijun, et al.
Publicado: (2021)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

[(18)F]FBEM-Z(HER2:342)-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography
por: Kramer-Marek, Gabriela, et al.
Publicado: (2007)

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
por: Xu, Tianqi, et al.
Publicado: (2022)

Application of a Novel (68)Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
por: Miao, Haitao, et al.
Publicado: (2022)

The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer
por: Cai, Wenbin, et al.
Publicado: (2023)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
por: Liu-Kreyche, Peggy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ju7fvhbau05nd32tnli37976d1